Hims & Hers Health, Inc. (HIMS) stock
Close on Nov 16, 2026Market cap $4.33BP/E –Yield –
Earnings
Hims & Hers Health's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Hims & Hers Health's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 22, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026after the close | $890.40M | +48.6% | -$0.14 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 10, 2026after the close | $753.20M | +38.3% | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 11, 2026after the close | $608.10M | +3.8% | -$0.40 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 23, 2026after the close | $617.80M | +28.4% | $0.08 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 3, 2025after the close | $599.00M | +49.2% | $0.06 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 4, 2025after the close | $544.80M | +72.6% | $0.17 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 5, 2025after the close | $586.00M | +110.6% | $0.20 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 24, 2025after the close | $481.10M | +95.1% | $0.11 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 4, 2024after the close | $401.60M | +77.2% | $0.32 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 5, 2024after the close | $315.60M | +51.8% | $0.06 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 6, 2024after the close | $278.20M | +45.8% | $0.05 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 26, 2024after the close | $246.60M | +47.5% | $0.01 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 6, 2023after the close | $226.70M | +56.6% | -$0.04 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 7, 2023after the close | $207.90M | +83.0% | -$0.03 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 8, 2023after the close | $190.80M | +88.4% | -$0.05 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 27, 2023after the close | $167.20M | +97.4% | -$0.05 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 7, 2022after the close | $144.80M | +95.1% | -$0.09 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 8, 2022after the close | $113.60M | – | -$0.10 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 9, 2022during market hours | $101.30M | – | -$0.08 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 22, 2022during market hours | $84.70M | – | -$0.15 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021during market hours | $74.20M | – | -$0.08 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 11, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 4, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 18, 2021during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Hims & Hers Health's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| RevenueGAAP | Q4 FY2026 | $875.00M – $895.00M | – | New | Nov 9, 2026 |
| Adjusted EBITDAnon-GAAP | Q4 FY2026 | $70.00M – $90.00M | – | New | Nov 9, 2026 |
| Adjusted EBITDA marginnon-GAAP | Q4 FY2026 | 8% – 10% | – | New | Nov 9, 2026 |
| RevenueGAAP | FY2026 | $3.13B – $3.15B | – | New | Nov 9, 2026 |
| Revenue | FY2026 | $3.10B – $3.30B | $2.80B – $3.00B | Raised | Aug 10, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $257.00M – $277.00M | – | New | Nov 9, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $275.00M – $325.00M | $275.00M – $350.00M | Lowered | Aug 10, 2026 |
| Adjusted EBITDA marginnon-GAAP | FY2026 | 8% – 9% | – | New | Nov 9, 2026 |
| Adjusted EBITDA marginnon-GAAP | FY2026 | 10% – 12% | 11% – 13% | Lowered | May 11, 2026 |
| Revenue | FY2030 | $6.50B | – | New | May 5, 2025 |
| Adjusted EBITDAnon-GAAP | FY2030 | $1.30B | – | New | May 5, 2025 |
Guidance vs results
The last range Hims & Hers Health gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q3 FY2026 | Revenue | $880.00M – $900.00M | $890.40M | Within range |
| Q2 FY2026 | Revenue | $680.00M – $700.00M | $753.20M | Above range |
| Q1 FY2026 | Revenue | $600.00M – $625.00M | $608.10M | Within range |
| FY2025 | Revenue | $2.34B – $2.36B | $2.35BΣ4Q | Within range |
| Q4 FY2025 | Revenue | $605.00M – $625.00M | $617.80M | Within range |
| Q3 FY2025 | Revenue | $570.00M – $590.00M | $599.00M | Above range |
| Q2 FY2025 | Revenue | $530.00M – $550.00M | $544.80M | Within range |
| Q1 FY2025 | Revenue | $520.00M – $540.00M | $586.00M | Above range |
| Q4 FY2024 | Revenue | $465.00M – $470.00M | $481.10M | Above range |
| Q3 FY2024 | Revenue | $375.00M – $380.00M | $401.60M | Above range |
| Q2 FY2024 | Revenue | $292.00M – $297.00M | $315.60M | Above range |
| Q1 FY2024 | Revenue | $267.00M – $272.00M | $278.20M | Above range |
| Q4 FY2023 | Revenue | $243.00M – $248.00M | $246.60M | Within range |
| Q3 FY2023 | Revenue | $217.00M – $222.00M | $226.70M | Above range |
| Q2 FY2023 | Revenue | $200.00M – $205.00M | $207.90M | Above range |
| Q1 FY2023 | Revenue | $175.00M – $180.00M | $190.80M | Above range |
| Q4 FY2022 | Revenue | $159.00M – $162.00M | $167.20M | Above range |
| Q3 FY2022 | Revenue | $129.00M – $132.00M | $144.80M | Above range |
| Q2 FY2022 | Revenue | $103.00M – $106.00M | $113.60M | Above range |
| Q1 FY2022 | Revenue | $90.00M – $93.00M | $101.30M | Above range |
| Q4 FY2021 | Revenue | $76.00M – $78.00M | $84.70M | Above range |
Guidance history
Every forecast Hims & Hers Health put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 9, 2026 | Adjusted EBITDA | FY2026 | $257.00M – $277.00M | New |
| Nov 9, 2026 | Adjusted EBITDA | Q4 FY2026 | $70.00M – $90.00M | New |
| Nov 9, 2026 | Adjusted EBITDA margin | Q4 FY2026 | 8% – 10% | New |
| Nov 9, 2026 | Adjusted EBITDA margin | FY2026 | 8% – 9% | New |
| Nov 9, 2026 | Revenue | FY2026 | $3.13B – $3.15B | New |
| Nov 9, 2026 | Revenue | Q4 FY2026 | $875.00M – $895.00M | New |
| Aug 10, 2026 | Adjusted EBITDA | FY2026 | $275.00M – $325.00M | Lowered |
| Aug 10, 2026 | Adjusted EBITDA | Q3 FY2026 | $75.00M – $95.00M | New |
| Aug 10, 2026 | Revenue | Q3 FY2026 | $880.00M – $900.00M | New |
| Aug 10, 2026 | Revenue | FY2026 | $3.10B – $3.30B | Raised |
| May 11, 2026 | Adjusted EBITDA | Q2 FY2026 | $35.00M – $55.00M | New |
| May 11, 2026 | Adjusted EBITDA | FY2026 | $275.00M – $350.00M | Lowered |
| May 11, 2026 | Adjusted EBITDA margin | FY2026 | 10% – 12% | Lowered |
| May 11, 2026 | Adjusted EBITDA margin | Q2 FY2026 | 5% – 8% | New |
| May 11, 2026 | Revenue | FY2026 | $2.80B – $3.00B | Raised |
| May 11, 2026 | Revenue | Q2 FY2026 | $680.00M – $700.00M | New |
| Feb 23, 2026 | Adjusted EBITDA | Q1 FY2026 | $35.00M – $55.00M | New |
| Feb 23, 2026 | Adjusted EBITDA | FY2026 | $300.00M – $375.00M | New |
| Feb 23, 2026 | Adjusted EBITDA margin | FY2026 | 11% – 13% | New |
| Feb 23, 2026 | Adjusted EBITDA margin | Q1 FY2026 | 6% – 9% | New |
| Feb 23, 2026 | Revenue | FY2026 | $2.70B – $2.90B | New |
| Feb 23, 2026 | Revenue | Q1 FY2026 | $600.00M – $625.00M | New |
| Nov 3, 2025 | Adjusted EBITDA | FY2025 | $307.00M – $317.00M | New |
| Nov 3, 2025 | Adjusted EBITDA | Q4 FY2025 | $55.00M – $65.00M | New |
| Nov 3, 2025 | Adjusted EBITDA margin | FY2025 | 13% | New |
| Nov 3, 2025 | Adjusted EBITDA margin | Q4 FY2025 | 9% – 10% | New |
| Nov 3, 2025 | Revenue | Q4 FY2025 | $605.00M – $625.00M | New |
| Nov 3, 2025 | Revenue | FY2025 | $2.34B – $2.36B | New |
| Aug 4, 2025 | Adjusted EBITDA | FY2025 | $295.00M – $335.00M | Reaffirmed |
| Aug 4, 2025 | Adjusted EBITDA | Q3 FY2025 | $60.00M – $70.00M | New |
| Aug 4, 2025 | Adjusted EBITDA margin | FY2025 | 13% – 14% | Reaffirmed |
| Aug 4, 2025 | Adjusted EBITDA margin | Q3 FY2025 | 11% – 12% | New |
| Aug 4, 2025 | Revenue | FY2025 | $2.30B – $2.40B | Reaffirmed |
| Aug 4, 2025 | Revenue | Q3 FY2025 | $570.00M – $590.00M | New |
| May 5, 2025 | Adjusted EBITDA | Q2 FY2025 | $65.00M – $75.00M | New |
| May 5, 2025 | Adjusted EBITDA | FY2025 | $295.00M – $335.00M | Raised |
| May 5, 2025 | Adjusted EBITDA | FY2030 | $1.30B | New |
| May 5, 2025 | Adjusted EBITDA margin | Q2 FY2025 | 12% – 14% | New |
| May 5, 2025 | Adjusted EBITDA margin | FY2025 | 13% – 14% | Raised |
| May 5, 2025 | Revenue | FY2025 | $2.30B – $2.40B | Reaffirmed |
| May 5, 2025 | Revenue | FY2030 | $6.50B | New |
| May 5, 2025 | Revenue | Q2 FY2025 | $530.00M – $550.00M | New |
| Feb 24, 2025 | Adjusted EBITDA | Q1 FY2025 | $55.00M – $65.00M | New |
| Feb 24, 2025 | Adjusted EBITDA | FY2025 | $270.00M – $320.00M | New |
| Feb 24, 2025 | Adjusted EBITDA margin | Q1 FY2025 | 11% – 12% | New |
| Feb 24, 2025 | Adjusted EBITDA margin | FY2025 | 12% – 13% | New |
| Feb 24, 2025 | Revenue | FY2025 | $2.30B – $2.40B | New |
| Feb 24, 2025 | Revenue | Q1 FY2025 | $520.00M – $540.00M | New |
| Nov 4, 2024 | Adjusted EBITDA | Q4 FY2024 | $50.00M – $55.00M | New |
| Nov 4, 2024 | Adjusted EBITDA | FY2024 | $173.00M – $178.00M | Raised |
| Nov 4, 2024 | Adjusted EBITDA margin | Q4 FY2024 | 11% – 12% | New |
| Nov 4, 2024 | Adjusted EBITDA margin | FY2024 | 12% | Raised |
| Nov 4, 2024 | Revenue | FY2024 | $1.46B – $1.47B | Raised |
| Nov 4, 2024 | Revenue | Q4 FY2024 | $465.00M – $470.00M | New |
| Aug 5, 2024 | Adjusted EBITDA | Q3 FY2024 | $35.00M – $40.00M | New |
| Aug 5, 2024 | Adjusted EBITDA | FY2024 | $140.00M – $155.00M | Raised |
| Aug 5, 2024 | Adjusted EBITDA margin | Q3 FY2024 | 9% – 11% | New |
| Aug 5, 2024 | Adjusted EBITDA margin | FY2024 | 10% – 11% | Reaffirmed |
| Aug 5, 2024 | Revenue | FY2024 | $1.37B – $1.40B | Raised |
| Aug 5, 2024 | Revenue | Q3 FY2024 | $375.00M – $380.00M | New |
| May 6, 2024 | Adjusted EBITDA | FY2024 | $120.00M – $135.00M | Raised |
| May 6, 2024 | Adjusted EBITDA | Q2 FY2024 | $30.00M – $35.00M | New |
| May 6, 2024 | Adjusted EBITDA margin | FY2024 | 10% – 11% | Raised |
| May 6, 2024 | Adjusted EBITDA margin | Q2 FY2024 | 10% – 12% | New |
| May 6, 2024 | Revenue | FY2024 | $1.20B – $1.23B | New |
| May 6, 2024 | Revenue | Q2 FY2024 | $292.00M – $297.00M | New |
| Feb 26, 2024 | Adjusted EBITDA | Q1 FY2024 | $22.00M – $27.00M | New |
| Feb 26, 2024 | Adjusted EBITDA | FY2024 | $100.00M – $120.00M | New |
| Feb 26, 2024 | Adjusted EBITDA margin | Q1 FY2024 | 8% – 10% | New |
| Feb 26, 2024 | Adjusted EBITDA margin | FY2024 | 9% – 10% | New |
| Feb 26, 2024 | Revenue | FY2024 | $1.17B – $1.20B | New |
| Feb 26, 2024 | Revenue | Q1 FY2024 | $267.00M – $272.00M | New |
| Nov 6, 2023 | Adjusted EBITDA | Q4 FY2023 | $14.00M – $17.00M | New |
| Nov 6, 2023 | Adjusted EBITDA | FY2023 | $43.00M – $46.00M | Raised |
| Nov 6, 2023 | Adjusted EBITDA margin | FY2023 | 5% | Raised |
| Nov 6, 2023 | Adjusted EBITDA margin | Q4 FY2023 | 6% – 7% | New |
| Nov 6, 2023 | Revenue | FY2023 | $868.00M – $873.00M | Raised |
| Nov 6, 2023 | Revenue | Q4 FY2023 | $243.00M – $248.00M | New |
| Aug 7, 2023 | Adjusted EBITDA | FY2023 | $35.00M – $40.00M | Raised |
| Aug 7, 2023 | Adjusted EBITDA | Q3 FY2023 | $10.00M – $13.00M | New |
| Aug 7, 2023 | Adjusted EBITDA margin | FY2023 | 4% – 5% | Raised |
| Aug 7, 2023 | Adjusted EBITDA margin | Q3 FY2023 | 5% – 6% | New |
| Aug 7, 2023 | Revenue | Q3 FY2023 | $217.00M – $222.00M | New |
| Aug 7, 2023 | Revenue | FY2023 | $830.00M – $850.00M | Raised |
| May 8, 2023 | Adjusted EBITDA | Q2 FY2023 | $4.00M – $7.00M | New |
| May 8, 2023 | Adjusted EBITDA | FY2023 | $25.00M – $30.00M | Raised |
| May 8, 2023 | Revenue | FY2023 | $810.00M – $830.00M | Raised |
| May 8, 2023 | Revenue | Q2 FY2023 | $200.00M – $205.00M | New |
| Feb 27, 2023 | Adjusted EBITDA | FY2023 | $20.00M – $30.00M | New |
| Feb 27, 2023 | Adjusted EBITDA | Q1 FY2023 | $3.00M – $6.00M | New |
| Feb 27, 2023 | Adjusted EBITDA margin | Q1 FY2023 | 2% – 3% | New |
| Feb 27, 2023 | Adjusted EBITDA margin | FY2023 | 3% – 4% | New |
| Feb 27, 2023 | Revenue | FY2023 | $735.00M – $755.00M | New |
| Feb 27, 2023 | Revenue | Q1 FY2023 | $175.00M – $180.00M | New |
| Nov 7, 2022 | Adjusted EBITDA | Q4 FY2022 | $0 – $2.00M | New |
| Nov 7, 2022 | Adjusted EBITDA | FY2022 | -$20.00M – -$18.00M | Raised |
| Nov 7, 2022 | Adjusted EBITDA margin | Q4 FY2022 | 0% – 1% | New |
| Nov 7, 2022 | Adjusted EBITDA margin | FY2022 | -4% – -3% | Raised |
| Nov 7, 2022 | Revenue | FY2022 | $519.00M – $522.00M | Raised |
| Nov 7, 2022 | Revenue | Q4 FY2022 | $159.00M – $162.00M | New |
| Aug 8, 2022 | Adjusted EBITDA | Q3 FY2022 | -$9.00M – -$7.00M | New |
| Aug 8, 2022 | Adjusted EBITDA | FY2022 | -$27.00M – -$20.00M | Raised |
| Aug 8, 2022 | Adjusted EBITDA margin | Q3 FY2022 | -7% – -5% | New |
| Aug 8, 2022 | Adjusted EBITDA margin | FY2022 | -6% – -4% | Raised |
| Aug 8, 2022 | Revenue | FY2022 | $470.00M – $485.00M | Raised |
| Aug 8, 2022 | Revenue | Q3 FY2022 | $129.00M – $132.00M | New |
| May 9, 2022 | Adjusted EBITDA | Q2 FY2022 | -$9.00M – -$7.00M | New |
| May 9, 2022 | Adjusted EBITDA | FY2022 | -$30.00M – -$20.00M | Reaffirmed |
| May 9, 2022 | Adjusted EBITDA margin | FY2022 | -7% – -5% | New |
| May 9, 2022 | Adjusted EBITDA margin | Q2 FY2022 | -9% – -7% | New |
| May 9, 2022 | Revenue | FY2022 | $410.00M – $425.00M | Raised |
| May 9, 2022 | Revenue | Q2 FY2022 | $103.00M – $106.00M | New |
| Feb 22, 2022 | Adjusted EBITDA | FY2022 | -$30.00M – -$20.00M | New |
| Feb 22, 2022 | Adjusted EBITDA | Q1 FY2022 | -$12.00M – -$10.00M | New |
| Feb 22, 2022 | Revenue | Q1 FY2022 | $90.00M – $93.00M | New |
| Feb 22, 2022 | Revenue | FY2022 | $365.00M – $380.00M | New |
| Nov 10, 2021 | Adjusted EBITDA | Q4 FY2021 | -$14.00M – -$12.00M | New |
| Nov 10, 2021 | Adjusted EBITDA | FY2021 | -$37.00M – -$35.00M | New |
| Nov 10, 2021 | Revenue | Q4 FY2021 | $76.00M – $78.00M | New |
| Nov 10, 2021 | Revenue | FY2021 | $263.00M – $265.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Hims & Hers Health filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- News
- Results
- Update
- Results
- Results
- Update
- Results
- Results
- Results
- Results
- News
See a number that looks wrong?